Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gamma-glutamylcysteine is a naturally occurring dipeptide composed of gamma-glutamate and cysteine. It is an intermediate in the biosynthesis of glutathione, formed by the enzyme glutamate-cysteine ligase and subsequently converted to glutathione by glutathione synthase. As a precursor to glutathione (GSH), it plays a critical role in cellular antioxidant defense mechanisms. Supplementation with gamma-glutamylcysteine has been shown to increase intracellular GSH levels, reduce oxidative stress, apoptosis, and inflammation in human cells, suggesting potential neuroprotective effects and possible therapeutic use for disorders associated with GSH depletion such as neurodegenerative diseases[5][4]. It is primarily used for research purposes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gamma-Glutamylcysteine.